Cognitive impairment after recovery from COVID-19 : Frequency, profile, and relationships with clinical and laboratory indices
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved..
Cognitive impairment (CI) is regarded as a remarkable burden in COVID-19 survivors. Its prevalence and profile, and relationships with the disease clinical and laboratory indices, remain unclear. The present study investigated, in a large sample of patients recovered from COVID-19, the frequency of CI with both a face-to-face screening tool and comprehensive test battery (MCCB). The study also evaluated the profile of CI and its relationships with COVID-19 clinical and laboratory indices and with psychopathological features. Out of 1344 subjects assessed for eligibility, 736 completed the screening phase 11 months after the COVID-19 infection; 402 participated in the baseline phase and completed an in depth cognitive, clinical and laboratory assessment about one month later. More than one third of the screened subjects presented a CI (COG+); it was associated to age, education, male gender, COVID-19 severity, and presence of anosmia, dyspnea at rest and exertional dyspnea during the acute phase. COG+ subjects showed a higher severity of depression, anxiety and post-traumatic distress, and worse global functioning, than subjects without CI. The MCCB showed that 45% of the subjects had a CI involving attention, working memory, verbal learning, visual learning, and reasoning and problem solving. Finally, neurocognitive functioning was inversely correlated with LDH blood levels, a potential biomarker of disease severity. According to our findings, cognitive functioning should be routinely and periodically assessed in COVID-19 patients, especially in older subjects, who experienced more severe COVID-19 symptoms. In case of persisting dysfunctions cognitive training programs should be considered as treatment strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology - 79(2024) vom: 01. Feb., Seite 22-31 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 06.02.2024 Date Revised 06.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.euroneuro.2023.11.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365558605 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365558605 | ||
| 003 | DE-627 | ||
| 005 | 20240206232036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euroneuro.2023.11.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM365558605 | ||
| 035 | |a (NLM)38065006 | ||
| 035 | |a (PII)S0924-977X(23)00707-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Galderisi, Silvana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cognitive impairment after recovery from COVID-19 |b Frequency, profile, and relationships with clinical and laboratory indices |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.02.2024 | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Cognitive impairment (CI) is regarded as a remarkable burden in COVID-19 survivors. Its prevalence and profile, and relationships with the disease clinical and laboratory indices, remain unclear. The present study investigated, in a large sample of patients recovered from COVID-19, the frequency of CI with both a face-to-face screening tool and comprehensive test battery (MCCB). The study also evaluated the profile of CI and its relationships with COVID-19 clinical and laboratory indices and with psychopathological features. Out of 1344 subjects assessed for eligibility, 736 completed the screening phase 11 months after the COVID-19 infection; 402 participated in the baseline phase and completed an in depth cognitive, clinical and laboratory assessment about one month later. More than one third of the screened subjects presented a CI (COG+); it was associated to age, education, male gender, COVID-19 severity, and presence of anosmia, dyspnea at rest and exertional dyspnea during the acute phase. COG+ subjects showed a higher severity of depression, anxiety and post-traumatic distress, and worse global functioning, than subjects without CI. The MCCB showed that 45% of the subjects had a CI involving attention, working memory, verbal learning, visual learning, and reasoning and problem solving. Finally, neurocognitive functioning was inversely correlated with LDH blood levels, a potential biomarker of disease severity. According to our findings, cognitive functioning should be routinely and periodically assessed in COVID-19 patients, especially in older subjects, who experienced more severe COVID-19 symptoms. In case of persisting dysfunctions cognitive training programs should be considered as treatment strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical correlates | |
| 650 | 4 | |a Cognitive domains | |
| 650 | 4 | |a Cognitive impairment prevalence | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Perrottelli, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Giuliani, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Pisaturo, Maria Antonietta |e verfasserin |4 aut | |
| 700 | 1 | |a Monteleone, Palmiero |e verfasserin |4 aut | |
| 700 | 1 | |a Pagliano, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Vita, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Muiesan, Maria Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Amore, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Bassetti, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Siracusano, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Mucci, Armida |e verfasserin |4 aut | |
| 700 | 1 | |a Bucci, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Cascino, Giammarco |e verfasserin |4 aut | |
| 700 | 1 | |a Barlati, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Amerio, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Di Lorenzo, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Niolu, Cinzia |e verfasserin |4 aut | |
| 700 | 1 | |a Coppola, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Maj, Mario |e verfasserin |4 aut | |
| 700 | 0 | |a Italian Working Group on COVID-19 Cognitive and Psychopathological Sequelae |e verfasserin |4 aut | |
| 700 | 1 | |a Onorato, Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Giugliano, Gennaro |e investigator |4 oth | |
| 700 | 1 | |a Livoti, Maria Laura |e investigator |4 oth | |
| 700 | 1 | |a Caulo, Chiara |e investigator |4 oth | |
| 700 | 1 | |a Ceres, Rossella |e investigator |4 oth | |
| 700 | 1 | |a Polverino, Benedetto Maria |e investigator |4 oth | |
| 700 | 1 | |a Nibbio, Gabriele |e investigator |4 oth | |
| 700 | 1 | |a Pinton, Irene Calzavara |e investigator |4 oth | |
| 700 | 1 | |a Sala, Emma |e investigator |4 oth | |
| 700 | 1 | |a Aguglia, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Vena, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Barisione, Emanuela |e investigator |4 oth | |
| 700 | 1 | |a Bianciardi, Emanuela |e investigator |4 oth | |
| 700 | 1 | |a Nastro, Federico Fiori |e investigator |4 oth | |
| 700 | 1 | |a Pelle, Martina |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology |d 1997 |g 79(2024) vom: 01. Feb., Seite 22-31 |w (DE-627)NLM013028618 |x 1873-7862 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2024 |g day:01 |g month:02 |g pages:22-31 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.euroneuro.2023.11.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2024 |b 01 |c 02 |h 22-31 | ||